Posttransplant reduction in preexisting donor‐specific antibody levels after belatacept‐ versus cyclosporine‐based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT‐EXT

Những quyển sách tương tự

• De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT studies
  Bằng: Bray, R. A., et al.
  Được phát hành: (2018)
• Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study
  Bằng: Durrbach, A., et al.
  Được phát hành: (2016)
• Belatacept-versus Cyclosporine-Based Immunosuppression in Renal Transplant Recipients with Pre-existing Diabetes
  Bằng: Rostaing, Lionel, et al.
  Được phát hành: (2011)
• The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.
  Bằng: Nalesnik, M. A., et al.
  Được phát hành: (1988)
• Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
  Bằng: Vincenti, F., et al.
  Được phát hành: (2017)